Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Roxadustat Market Size And Revenue Outlook Through 2030
The roxadustat market has experienced robust expansion in recent years. Forecasts suggest it will enlarge from $6.86 billion in 2025 to $7.33 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.9%. This past expansion can be ascribed to a high incidence of chronic kidney disease, reliance on erythropoiesis-stimulating agents, hospital-centric anemia management, the limited availability of oral anemia treatments, and an increase in dialysis centers.
The roxadustat market size is projected to witness robust expansion over the next few years, set to achieve $9.56 billion in 2030, growing at a compound annual growth rate (CAGR) of 6.9%. The impetus for this growth during the forecast period stems from the increasing global burden of anemia, a burgeoning preference for oral therapeutic options, an expanding chronic kidney disease (CKD) patient demographic, the rise of outpatient anemia management, and enhanced access to innovative anemia drugs. Prominent trends anticipated within this period include the escalating adoption of oral anemia treatments, the growing utilization of HIF-PHI drugs, an intensified focus on CKD-associated anemia, a strategic shift away from injectable ESAs, and a broader accessibility to anemia treatment solutions.
Get A Free Sample Report With In-Depth Market Insights:
Roxadustat Market Growth Momentum: What Factors Are Shaping Demand?
An increasing prevalence of chronic kidney disease (CKD) is anticipated to drive expansion in the Roxadustat market in the future. CKD is characterized as a persistent ailment where the kidneys progressively diminish their functional capacity, potentially resulting in renal failure without appropriate intervention. Globally, the incidence of chronic kidney disease is escalating, attributable to factors like an aging demographic, a surge in diabetes and hypertension cases, and detrimental lifestyle choices. Roxadustat offers a management solution for chronic kidney disease by prompting erythropoietin synthesis, which in turn boosts red blood cell creation, thereby counteracting anemia frequently linked with CKD and enhancing both renal function and patient quality of life. A notable example illustrating this trend is the projection by Kidney Research UK, a UK-based charity, which stated in June 2023 that by 2033, the population of individuals suffering from CKD stages 3–5 is predicted to escalate to 3.9 million. Consequently, the growing population affected by chronic kidney disease (CKD) is fueling the expansion of the Roxadustat market.
Roxadustat Market Segmentation: How Does The Market Break Down By Category?
The roxadustat market covered in this report is segmented –
1) By Type: 20mg, 50mg
2) By Product Formulation: Oral Tablets
3) By Distribution Channel: Hospitals, Specialty Pharmacies, Dialysis Centers
4) By End-User Application: Chronic Kidney Disease-Associated Anemia, Other Anemia Conditions
Roxadustat Market Trends Redefining Industry Growth
Major companies operating in the roxadustat market are concentrating on generating real world evidence, such as observational registry studies, to solidify the long-term value, safety, and utilization patterns of their HIF PH inhibitor therapy. Real world evidence encompasses clinical data gathered outside controlled trials, within routine practice settings, reflecting actual patient experiences. The roxadustat market facilitates this trend by sponsoring large-scale real-world studies that healthcare payers and regulators are increasingly depending on for their evaluations. For instance, in May 2024, Astellas Pharma, a UK based company, completed the launch of the WINE study via the WiNe Registry in Germany, which is a non interventional cohort study capturing clinical outcomes, dosing characteristics, and hemoglobin response in patients treated with EVRENZO (roxadustat). The insights obtained from that registry help illustrate roxadustat’s effectiveness in real-world CKD populations and contribute to long-term reimbursement decisions. Therefore, the generation of real-world evidence is driving the expansion of the roxadustat market.
Roxadustat Market Competitive Overview And Top Companies
Major companies operating in the roxadustat market are AstraZeneca PLC, Viatris Inc., Astellas Pharma Inc., Dr. Reddy’s Laboratories Ltd., Hetero Drugs Limited, Akebia Therapeutics Inc., Metrochem API Private Limited, FibroGen Inc., AMI Lifesciences, Lee Pharma Ltd., Faran Shimi Pharmaceutical Company, Maithri Drugs Pvt. Ltd., Clearsynth Labs Ltd., Bal Pharma, HEMA Pharmaceuticals Pvt. Ltd., Zhejiang Hengkang Pharmaceutical Co. Ltd., Kimia Biosciences Pvt. Ltd., Lewens Labs Pvt. Ltd., Hangzhou Longshine Bio-Tech Co. Ltd., Suzhou Biosyntech Co. Ltd., Shanvr Life Sciences Pvt. Ltd.
View The Full Roxadustat Market Report:
Roxadustat Market Largest Region: Which Geography Holds The Highest Market Share?
North America was the largest region in the Roxadustat market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the roxadustat market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
